Increased cost of illness among European patients with type 2 diabetes treated with insulin.
To investigate the association between outcomes and different escalating combinations of non-insulin medications vs. insulin.



Data were taken from the 2013 5EU NHWS, a cross-sectional survey including 62,000 respondents across France, Germany, Italy, Spain, and the UK. Costs were estimated from self-reported work impairment and healthcare visits using average wages and unit costs. Respondents taking antihyperglycemic medications (n = 2894) were compared according to treatment type using unadjusted comparisons followed by regression to adjust for confounders.



Insulin users had the highest costs and worse outcomes, a pattern that remained after adjustment for a range of sociodemographic and disease characteristics. Incremental direct costs were approximately €800. Incremental indirect costs, applicable only to the employed, were larger than incremental direct costs, but were statistically significant only relative to non-insulin monotherapy.



Escalation using oral agents rather than insulin is associated with better quality of life and lower costs, though these relationships may not be causal. Further research is warranted on escalation using oral agents among patients for whom insulin is not required.
a Janssen GCC , Dubai , United Arab Emirates.
Solomon
S
Nuhoho
b Kantar Health , Horsham , PA , USA.
Jeffrey
J
Vietri
c Janssen-Cilag Limited , High Wycombe , UK.
Melany
M
Worbes-Cerezo
D000328:Adult; D000368:Aged; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life
D007004:Hypoglycemic Agents; D007328:Insulin
Cost; diabetes; insulin therapies; non-insulin therapies; work productivity